의료정보 보호를 위한 옵트아웃(opt-out) 제도 도입의 필요성에 관한 연구

In the digital age, medical information serves as a critical resource for advancing personalized medicine and research. Digitalized medical data, such as electronic health records (EHR), genomic information, and biometric data, contribute to drug development and public health policymaking. However, as this data contains sensitive personal information, any misuse or breach can lead to severe privacy violations and economic losses. Therefore, establishing legal mechanisms to protect the rights of data subjects and ensure the safe use of medical information is essential. The pseudonymization system is a technical measure that transforms personal data to prevent direct identification, playing a vital role in balancing medical data protection and utilization. For instance, pseudonymized data used for medical research or public purposes allows researchers to analyze data without directly identifying individuals while maintaining its utility. However, pseudonymization has limitations, as re-identification remains possible when combined with additional information. This issue weakens the control of data subjects, increasing the risk of privacy violations and misuse, particularly for commercial purposes. If re-identified data is unlawfully utilized for profit, it could result in significant harm to data subjects. The opt-out system complements the limitations of pseudonymization by providing a legal mechanism that grants data subjects substantial control over their medical information. This system allows individuals to refuse the use of their data for specific purposes, especially commercial ones, effectively preventing the misuse of medical information and mitigating the risks of data breaches. In the United States, HIPAA offers flexibility by permitting the use of medical information without consent for essential purposes such as treatment, payment, and operations, while safeguarding data subjects’ rights through stringent security measures and sanctions. In contrast, the European Union’s GDPR requires explicit consent from data subjects and employs principles like pseudonymization and data minimization to balance data protection and utilization for public purposes. GDPR also minimizes the risk of re-identification to protect the privacy of data subjects. In South Korea, while the Personal Information Protection Act (PIPA) and the Medical Service Act provide basic frameworks for data protection, they fall short in regulating the commercial use of pseudonymized data and ensuring the rights of data subjects. For example, there are no clear provisions regarding the commercial use of pseudonymized data, and mechanisms for individuals to withdraw or refuse the use of their data are insufficient. To address these gaps, it is necessary to introduce an opt-out system and establish a real-time control system. Such a system would enable data subjects to monitor, withdraw, or refuse the use of their information at any time, preventing misuse and abuse of data. Additionally, imposing stringent penalties for re-identification attempts would strengthen the protection of data subjects’ rights and enhance transparency in medical data usage. In conclusion, legal and institutional improvements are required to address the limitations of pseudonymization and implement an opt-out system. By creating an environment where data subjects can freely control their information, it is possible to achieve a balance between the secure use of medical data and the protection of personal information, ultimately contributing to the enhancement of medical services and the advancement of research.